Abstract
Objective: To understanding, from the perspective of the patient who had Covid-19, the vaccination against the disease., from the patient's perspective. Methods: This is an exploratory, descriptive and qualitative study. For the selection of participants, we used the database that gathers information and monitors the Covid-19, fed by the managers of the Basic Health Units of the city of Paranavaí-PR, from the random selection of 150 telephone contacts. The academics contacted the individuals who are part of the database and who had a confirmed diagnosis for Covid-19. Content analysis was used to process the data. Results: 23 interviews were conducted, 21 individuals received complete Covid-19 vaccination schedules with the two doses and the booster dose, and only two incomplete schedules with only one dose. Three categories emerged: "Myths, uncertainties and lack of clarification about the vaccine, disease and treatment"; "Attitudes and feelings surrounding the acceptance and refusal of vaccination"; "post-Covid-19 sequelae, life changes and feelings during social isolation". Conclusion: From this study, it was observed that there are doubts and negative feelings concerning the Covid-19 pandemic and vaccination. Such questioning may be related to the mass dissemination of untrue information.
References
ARAÚJO TME, et al. Aceitação da vacina contra COVID-19 entre público diagnosticado com síndrome gripal. Acta Paulista de Enfermagem, São Paulo. 2021; 34: AO000086.
BARDIN L. Análise de conteúdo. Traduzido por Luís Antero Reto, Augusto Pinheiro. São Paulo. 2011; 70: 25765.
BRAGATTO MG, et al. Estudo das sequelas neuroanatômicas associadas à Síndrome Pós-COVID-19. Revista Eletrônica Acervo Saúde. 2021; 13: e8759.
BRASIL. Ministério da Saúde. Brasil tem 80% da população alvo com duas doses de vacina contra a Covid-19. Disponível em: https://www.gov.br/pt-br/noticias/saude-e-vigilancia-sanitaria/2021/12/brasil-tem-80-da-populacao-alvo-com-duas-doses-de-vacina-contra-a-covid-19. Acesso em: 29 dez. 2021.
BRASIL. Ministério da Saúde. Portaria Nº 188, de 3 de fevereiro de 2020 declara Emergência em Saúde Pública de importância Nacional (ESPIN) em decorrência da Infecção Humana pelo novo Coronavírus (2019-nCoV). Disponível em: https://bvsms.saude.gov.br/bvs/saudelegis/gm/2020/prt0188_04_02_2020.html. Acesso em: 03 maio 2023.
BRASIL. Ministério da Saúde. Secretaria de Vigilância em Saúde. Guia de Vigilância Epidemiológica Covid-19: Emergência de Saúde Pública de Importância Nacional pela Doença pelo Coronavírus. 2019; 4: 978-65-5993-025-8.
CARDOSO T. Campanha de desinformação sobre vacina contra covid avança com testes no Brasil. Disponível em: https://jornal.usp.br/ciencias/campanha-de-desinformacao-sobre-vacina-contra-covid-avanca-com-testes-no-brasil/. Acesso em: 03 maio 2023.
Centers For Disease Control And Prevention. National Center for Immunization and Respiratory Diseases (NCIRD). Disponível em: https://www.cdc.gov/ncird/index.html. Acesso em: 02 maio 2023.
COUTO MT, et. al. Considerações sobre o impacto da covid-19 na relação indivíduo-sociedade: da hesitação vacinal ao clamor por uma vacina. Saúde e Sociedade. 2021; 30: 12902021200450.
DAYNES E, et al. Early experiences of rehabilitation for individuals post-COVID to improve fatigue, breathlessness exercise capacity and cognition – A cohort study. Chronic Respiratory Disease. 2021; 18: 14799731211015691.
DEMECO A, et al. Rehabilitation of patients post-COVID-19 infection: a literature review. Journal Of International Medical Research. 2020; 48: 0300060520948382.
FRANCO JM, et al. Sequelas Pós-covid-19. Anais Congrega Mic-Isbn Dev. 2021; 17: 329-335.
FREDERIKSEN LSF, et al. The Long Road Toward COVID-19 Herd Immunity: vaccine platform technologies and mass immunization strategies. Frontiers In Immunology. 2021; 11.
GIL AC. Métodos e técnicas de pesquisa social. Editora Atlas SA. 2008; 6: 978-85-224-5142-5.
HUANG C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020; 395: 497-506.
HUANG Y e ZHAO N. Generalized anxiety disorder, depressive symptoms and sleep quality during COVID-19 outbreak in China: a web-based cross-sectional survey. Psychiatry Research. 2020; 288.
LAKATOS EM e MARCONI MA. Fundamentos de Metodologia Científica. Atlas. São Paulo. 2003; 5: 85-224-3397-6.
LOCKYER B, et al. Understanding COVID‐19 misinformation and vaccine hesitancy in context: findings from a qualitative study involving citizens in bradford, UK. Health Expectations. 2021; 24: e13240.
LURIE N, et al. Developing Covid-19 Vaccines at Pandemic Speed. New England Journal Of Medicine. 2020; 382: 2005630.
MARTINS KM, et al. A importância da imunização: revisão integrativa. Revista de Iniciação Científica e Extensão. 2019; 2(2): 96-101.
MATOS CCSA, et al. Vaccine hesitancy in the global south: towards a critical perspective on global health. Global Public Health. 2021; 17: 1912138.
OPAS. Organização Pan-Americana de Saúde. Com 14 países que ainda não vacinaram 40% de sua população, Américas continuam sendo região mais desigual do mundo na luta contra COVID-19. Disponível em: https://www.paho.org/pt/noticias/2-2-2022-com-14-paises-que-ainda-nao-vacinaram-40-sua-populacao-americas-continuam-sendo. Acesso em: 04 abr. 2023.
ORNELL F, et al. Pandemia de medo e Covid-19: impacto na saúde mental e possíveis estratégias. Debates em Psiquiatria, Rio de Janeiro, 2020; 10(2): 12-6.
SOARES CSA e FONSECA CLR. Atenção primária à saúde em tempos de pandemia. Jmphc | Journal of Management & Primary Health Care. 2020; 12: 1-11.
SILVA AP, et al. COVID-19 in the municipalities of Botucatu and Serrana, São Paulo, Brazil, the effects of lethality and mortality. Journal of Human Growth and Development. 2022; 32(2): e13255.
TONG A, et al. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care. 2007; 19: 349–357.
WHO. World Health Organization. Novel Coronavirus (2019-nCoV) technical guidance. Genebra, 2020. Disponível em: shorturl.at/dkrKU. Acesso em: 4 abr. 2023.
